For research use only. Not for therapeutic Use.
PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM[1].
| Catalog Number | R039701 |
| CAS Number | 1407966-77-1 |
| Synonyms | 3-[4-amino-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]pyrazolo[3,4-d]pyrimidin-3-yl]-N-(3-methyl-4-propan-2-ylphenyl)benzamide |
| Molecular Formula | C30H33N7O2 |
| Purity | ≥95% |
| InChI | InChI=1S/C30H33N7O2/c1-5-25(38)36-13-7-10-23(16-36)37-29-26(28(31)32-17-33-29)27(35-37)20-8-6-9-21(15-20)30(39)34-22-11-12-24(18(2)3)19(4)14-22/h5-6,8-9,11-12,14-15,17-18,23H,1,7,10,13,16H2,2-4H3,(H,34,39)(H2,31,32,33)/t23-/m1/s1 |
| InChIKey | CGJVMKJGKFEHTL-HSZRJFAPSA-N |
| SMILES | CC1=C(C=CC(=C1)NC(=O)C2=CC=CC(=C2)C3=NN(C4=NC=NC(=C34)N)C5CCCN(C5)C(=O)C=C)C(C)C |
| Reference | [1]. Mamand S, et al. Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma. Sci Rep. 2018 Sep 21;8(1):14216. |
